Anti-ebola binding proteins and methods of use thereof

Anti-Ebola binder proteins, including sdAbs and their Fc fusion proteins, effectively neutralize Ebola virus by targeting specific glycoprotein epitopes, offering complete protection in mouse models and overcoming decoy strategies, addressing the limitations of current treatments.

WO2026128718A2 Publication Date: 2026-06-18REGENTS OF THE UNIVERSITY OF MINNESOTA
0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
REGENTS OF THE UNIVERSITY OF MINNESOTA
Filing Date
2025-12-11
Publication Date
2026-06-18

AI Technical Summary

⚠Technical Problem

Current treatments for Ebola virus infections have modest efficacy, with existing FDA-approved antibody drugs reducing fatality rates only to about 35%, and there is a need for more effective and accessible treatment strategies due to the virus's high fatality rate and ability to remain dormant in humans.

⚗Method used

Development of anti-Ebola binder proteins, including single-domain antibodies (sdAbs) such as Nanosota-EBl and Nanosota-EB2, and their Fc fusion proteins, which target specific complementarity determining regions (CDRs) of the Ebola glycoprotein, as well as a bispecific inhibitor combining these sdAbs with a human Fc tag, to inhibit viral activity and neutralize infections.

🎯Benefits of technology

The anti-Ebola binder proteins demonstrate potent neutralization of Ebola virus, providing complete protection in mouse models and outperforming individual nanobodies, with the bispecific inhibitor showing synergistic effects by anchoring and recycling within endosomes to block viral entry.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

Certain embodiments of the invention provide isolated anti-Ebola single domain antibodies (sdAbs), as well as polypeptides and protein molecules comprising such sdAbs, including Fc fusion thereof, and bispecific anti-Ebola binder protein. Certain embodiments of the invention also provide methods of using these sdAbs, polypeptides and protein molecules for treating an Ebola virus infection.
Need to check novelty before this filing date? Find Prior Art